

2nd Swedish Medicinal Chemistry Symposium

September 25-26, 2019, Stockholm, Sweden

Program

Wednesday, September 25	
08.15	Registration
08.45	Opening remarks – House keeping Chair: Peter Sjö, DNDi
09.00	Plenary Lecture 1: Application of AI algorithms in the daily life of Medicinal Chemists – Status 2019 Werngard Czechtizky, AstraZeneca, Mölndal
09.45	Discovery of NUDIX and Glycosylase inhibitors Martin Scobie, Karolinska Institutet, Stockholm
10.15	Break
10.45	From screening to optimized lead on an "undruggable" aquaporin target for diabetes Thomas Brimert, Red Glead Discovery, Lund
11.15	Chemical synthesis of membrane-associated proteins: promising method for drug discovery Alesia Tietze, University of Gothenburg
11.45	Lunch Chair: Lena Ripa, AstraZeneca
12.45	Plenary Lecture 2: Elucidation of autophagy by chemical genetic approaches Yaowen Wu, Umeå University
13.30	Peptide-based drug discovery – new methods and applications Anja Sandström, Uppsala University
14.00	Accelerating drug discovery through automation Michael Kossenjans, AstraZeneca, Mölndal
14.30	Break
15.00	Arvid Carlsson memorial by Johan Wennerberg Chair: Åsa Rosenquist, Xspray Pharma
15.30	Flash Poster Presentations
16.30-	Cocktails & Poster Session
18.00	
Thursday, September 26	
08.45	House keeping Chair: Anna Linusson, Umeå University
09.00	The Swedish Pharmaceutical Society 2019 Medicinal Chemistry Award
09.15	Exploring the prevalence, function and regulation of short linear motif-based interactions Ylva Ivarsson, Uppsala University
09.45	Discovery of Mycobacterial Tolerance Inhibitors – Chemical disarming of drug resistance in Mycobacterium tuberculosis Fredrik Almqvist, Umeå University
10.15	Break
10.45	DHODH-inhibitors for the treatment of AML Ulrika Yngve, ScilifeLab, Uppsala University
11.15	Directed evolution in drug discovery Michael Gossing, AstraZeneca, Mölndal
11.45	Lunch Chair: <i>Åsa Rosenquist</i> , Xspray Pharma
12.45	Plenary Lecture 3: Conformational entropy and solvation entropy in protein-ligand binding Mikael Akke, Lund University
13.30	Poster Session and Break
14.30	Discovery of AZD5718, a novel 5-lipoxygenase activating protein (FLAP) inhibitor Malin Lemurell, AstraZeneca, Mölndal
15.00	Resin-acid derivatives as potassium channel openers and potential antiepileptic drugs Fredrik Elinder, Linköping University
15.30- 16.00	Concluding Remarks – End of Meeting

In co-operation with







Swedish Academy of Pharmaceutical Sciences